Systemic Scleroderma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Systemic Scleroderma Market Outlook

Thelansis’s “Systemic Scleroderma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Systemic Scleroderma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Systemic Scleroderma Overview

Scleroderma, or Systemic sclerosis (SS), is a connective tissue disorder primarily marked by skin thickening and hardening. It comes in two main forms: localized and systemic. Localized scleroderma primarily affects the skin, possibly involving muscles and bones. On the other hand, systemic scleroderma impacts internal organs like the digestive tract, heart, lungs, and kidneys. The condition's severity and outcome vary, influenced by genetic and environmental factors. Silica and specific organic solvents pose risks for systemic scleroderma. Life expectancy in systemic sclerosis patients depends on the extent and severity of organ involvement. Survival rates range from 75 to 80% after five years, decreasing to 55% after ten years, 35 to 40% after 15 years, and 25 to 30% after 20 years. Risk factors for higher mortality include advanced age at diagnosis, male gender, diffuse skin involvement, and organ complications.

• SSc's estimated incidence and prevalence in the United States were 15.1 cases per 100,000 person-years and 25.9 cases per 100,000 people, respectively.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: